Home » Market News » DirectorsTalk Highlights » Over 15,000 volunteer to be infected with COVID-19 to quicken vaccine development
Open Orphan PLC

Over 15,000 volunteer to be infected with COVID-19 to quicken vaccine development

The number of individuals who want to be infected as part of vaccine development continues to grow despite coronavirus emerging as the most fatal contagious disease.

A global advocacy group has registered over 15,000 volunteers who are ready to be transmitted with the pathogen as part of the vaccine formation trials.

The London-based hVIVO and Switzerland-based SGS are two leading clinical research organisations who are pursuing human trials to expedite the vaccine formation. The two companies, along with an array of global advocates backing their cause, called the human trials a necessary to save thousands of lives that would be lost due to delay in vaccine development.

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). 

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.